Deliver Your News to the World

Smallcapnewsrelease: (OTC: CLXN) CLX Medical Signs deal with Master Distributor for Europe


(Smallcapnewsrelease, August 08, 2008) – Jericho, N.Y. – CLX Medical (OTCBB:CLXN) announced today that it has reached and agreement with LETI Laboratories, a Barcelona based biopharmaceutical company, to serve as the sole importer of CLX’s subsidiary products into the European market
CLX Medical is focused on the launch and distribution of unique medical diagnostic testing products currently owns a majority interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets. More information regarding Zonda can be found at:
Laboratorios LETI, S.L. is an independent, family-owned, biopharmaceutical company dedicated to medicinal research. The company, founded in 1909, is based in Barcelona and its industrial plant and allergy research laboratory are located in Tres Cantos (Madrid). It has subsidiaries in Germany and Portugal and operates with exclusive distributors in different European countries, South America and Africa. LETI Laboratories will provide product support and product packaging control and coordinate sales to other European distributors.
For full news release please visit:

Smallcapnewsrelease Gainers are Baxter International Inc (NYSE: BAX), Luminex Corporation (Nasdaq: LMNX), Alcon Inc (NYSE: ACL), Stryker Corp. (NYSE:SYK), Covidien Ltd (NYSE: COV), Becton Dickinson and Co, (NYSE: BDX), Ligand Pharmaceuticals Inc (Nasdaq:LGND), ISTA Pharmaceuticals Inc (Nasdaq: ISTA).

Smallcapnewsrelease Decliners are Next Wave Wireless (Nasdaq: WAVE), Anadigics Inc (Nasdaq: ANAD),Omni Energy Services Corp (Nasdaq: OMNI), Coleman Cable Inc (Nasdaq: CCIX), Washington Mutual Inc (NYSE: WM), Chesapeake energy Corp. (NYSE: CHK), Berkshire Hathaway Inc(NYSE:BRK.A), Central European Media Enterprises LTD (Nasdaq: CETV).

For more information CLX Medical, Inc, visit us at

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Smallcapnewsrelease $2,495.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


 medical equipment
 bio- pharmeceutical

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.